These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 27412117

  • 1. Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.
    Gynther M, Peura L, Vernerová M, Leppänen J, Kärkkäinen J, Lehtonen M, Rautio J, Huttunen KM.
    Neurochem Res; 2016 Oct; 41(10):2797-2809. PubMed ID: 27412117
    [Abstract] [Full Text] [Related]

  • 2. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
    Puris E, Gynther M, Huttunen J, Auriola S, Huttunen KM.
    Eur J Pharm Sci; 2019 Mar 01; 129():99-109. PubMed ID: 30625368
    [Abstract] [Full Text] [Related]

  • 3. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
    Peura L, Malmioja K, Laine K, Leppänen J, Gynther M, Isotalo A, Rautio J.
    Mol Pharm; 2011 Oct 03; 8(5):1857-66. PubMed ID: 21770378
    [Abstract] [Full Text] [Related]

  • 4. L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs.
    Puris E, Gynther M, Huttunen J, Petsalo A, Huttunen KM.
    J Control Release; 2017 Sep 10; 261():93-104. PubMed ID: 28662899
    [Abstract] [Full Text] [Related]

  • 5. Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets.
    Puris E, Gynther M, de Lange ECM, Auriola S, Hammarlund-Udenaes M, Huttunen KM, Loryan I.
    Mol Pharm; 2019 Jul 01; 16(7):3261-3274. PubMed ID: 31180686
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.
    Peura L, Malmioja K, Huttunen K, Leppänen J, Hämäläinen M, Forsberg MM, Gynther M, Rautio J, Laine K.
    Pharm Res; 2013 Oct 01; 30(10):2523-37. PubMed ID: 24137801
    [Abstract] [Full Text] [Related]

  • 7. Amino acid ester prodrugs conjugated to the α-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1).
    Rautio J, Kärkkäinen J, Huttunen KM, Gynther M.
    Eur J Pharm Sci; 2015 Jan 23; 66():36-40. PubMed ID: 25305508
    [Abstract] [Full Text] [Related]

  • 8. Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs.
    Gynther M, Pickering DS, Spicer JA, Denny WA, Huttunen KM.
    Mol Pharm; 2016 Jul 05; 13(7):2484-91. PubMed ID: 27266990
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic analysis of ester prodrugs of valproic acid.
    Hadad S, Vree TB, van der Kleijn E, Bialer M.
    J Pharm Sci; 1992 Oct 05; 81(10):1047-50. PubMed ID: 1432619
    [Abstract] [Full Text] [Related]

  • 10. L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood-Brain Barrier and into Human and Mouse Brain Parenchymal Cells.
    Montaser AB, Järvinen J, Löffler S, Huttunen J, Auriola S, Lehtonen M, Jalkanen A, Huttunen KM.
    ACS Chem Neurosci; 2020 Dec 16; 11(24):4301-4315. PubMed ID: 33228353
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and anticonvulsant activity of three monoesteric prodrugs of valproic acid.
    Badir K, Haj-Yehia A, Vree TB, van der Kleijn E, Bialer M.
    Pharm Res; 1991 Jun 16; 8(6):750-3. PubMed ID: 2062805
    [Abstract] [Full Text] [Related]

  • 12. L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia.
    Huttunen J, Peltokangas S, Gynther M, Natunen T, Hiltunen M, Auriola S, Ruponen M, Vellonen KS, Huttunen KM.
    Sci Rep; 2019 Sep 06; 9(1):12860. PubMed ID: 31492955
    [Abstract] [Full Text] [Related]

  • 13. Brain uptake of ketoprofen-lysine prodrug in rats.
    Gynther M, Jalkanen A, Lehtonen M, Forsberg M, Laine K, Ropponen J, Leppänen J, Knuuti J, Rautio J.
    Int J Pharm; 2010 Oct 31; 399(1-2):121-8. PubMed ID: 20727958
    [Abstract] [Full Text] [Related]

  • 14. Large neutral amino acid transporter enables brain drug delivery via prodrugs.
    Gynther M, Laine K, Ropponen J, Leppänen J, Mannila A, Nevalainen T, Savolainen J, Järvinen T, Rautio J.
    J Med Chem; 2008 Feb 28; 51(4):932-6. PubMed ID: 18217702
    [Abstract] [Full Text] [Related]

  • 15. Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1).
    Ylikangas H, Malmioja K, Peura L, Gynther M, Nwachukwu EO, Leppänen J, Laine K, Rautio J, Lahtela-Kakkonen M, Huttunen KM, Poso A.
    ChemMedChem; 2014 Dec 28; 9(12):2699-707. PubMed ID: 25205473
    [Abstract] [Full Text] [Related]

  • 16. Characterisation, in-vitro and in-vivo evaluation of valproic acid-loaded nanoemulsion for improved brain bioavailability.
    Tan SF, Kirby BP, Stanslas J, Basri HB.
    J Pharm Pharmacol; 2017 Nov 28; 69(11):1447-1457. PubMed ID: 28809443
    [Abstract] [Full Text] [Related]

  • 17. Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug.
    Thiele NA, Kärkkäinen J, Sloan KB, Rautio J, Huttunen KM.
    Bioorg Med Chem Lett; 2018 Sep 15; 28(17):2856-2860. PubMed ID: 30055889
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid.
    Hadad S, Vree TB, van der Kleijn E, Bialer M.
    Biopharm Drug Dispos; 1993 Jan 15; 14(1):51-9. PubMed ID: 8427944
    [Abstract] [Full Text] [Related]

  • 19. Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion.
    Ylikangas H, Peura L, Malmioja K, Leppänen J, Laine K, Poso A, Lahtela-Kakkonen M, Rautio J.
    Eur J Pharm Sci; 2013 Feb 14; 48(3):523-31. PubMed ID: 23228412
    [Abstract] [Full Text] [Related]

  • 20. Structural Features Affecting the Interactions and Transportability of LAT1-Targeted Phenylalanine Drug Conjugates.
    Bahrami K, Järvinen J, Laitinen T, Reinisalo M, Honkakoski P, Poso A, Huttunen KM, Rautio J.
    Mol Pharm; 2023 Jan 02; 20(1):206-218. PubMed ID: 36394563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.